利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.03 秒)

    [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO
    1.
    发明申请
    [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO 有权
    [4-（6-羟基-7-取代-2,4-二氧代-1,4-二氢-2H-喹唑啉-3-基） - 苯基] -5-氯代 - 噻吩-2-基] - 磺酰基和形式 方法相关

    公开(公告)号：US20070123547A1

    公开(公告)日：2007-05-31

    申请号：US11556490

    申请日：2006-11-03

    申请人： Robert Scarborough ,  Wolin Huang ,  Mukund Mehrotra ,  Xiaoming Zhang ,  Hilary Cannon ,  Craig Grant ,  Carroll Scarborough

    发明人： Robert Scarborough ,  Wolin Huang ,  Mukund Mehrotra ,  Xiaoming Zhang ,  Hilary Cannon ,  Craig Grant ,  Carroll Scarborough

    IPC分类号： A61K31/517 ,  C07D409/02

    CPC分类号： C07D409/12

    摘要： The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

    摘要翻译： 本发明提供式（I）的新型磺酰脲化合物及其药学上可接受的衍生物及其多晶型物和无定形形式。 各种形式的化合物是有效的血小板ADP受体抑制剂，可用于各种药物组合物中，并且特别有效预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。 本发明还提供了一种制备此类化合物和形式并用于预防或治疗哺乳动物血栓形成和血栓形成相关病症的方法，包括施用治疗有效量的式（I）化合物或其药学上可接受的盐或其形式的步骤 。

    [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
    3.
    发明授权
    [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto 有权
    [4-（6-卤代-7-取代-2,4-二氧代-1,4-二氢-2H-喹唑啉-3-基） - 苯基] -5-氯 - 噻吩-2-基 - 磺酰脲，形成和 与之相关的方法

    公开(公告)号：US08058284B2

    公开(公告)日：2011-11-15

    申请号：US11556490

    申请日：2006-11-03

    申请人： Robert Scarborough ,  Carroll Anna Scarborough, legal representative ,  Wolin Huang ,  Mukund Mehrotra ,  Xiaoming Zhang ,  Hilary Cannon ,  Craig M. Grant

    发明人： Robert Scarborough ,  Wolin Huang ,  Mukund Mehrotra ,  Xiaoming Zhang ,  Hilary Cannon ,  Craig M. Grant

    IPC分类号： A61K31/517 ,  C07D409/12

    CPC分类号： C07D409/12

    摘要： The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

    摘要翻译： 本发明提供式（I）的新型磺酰脲化合物及其药学上可接受的衍生物及其多晶型物和无定形形式。 各种形式的化合物是有效的血小板ADP受体抑制剂，可用于各种药物组合物中，并且特别有效预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。 本发明还提供了一种制备此类化合物和形式并用于预防或治疗哺乳动物血栓形成和血栓形成相关病症的方法，包括施用治疗有效量的式（I）化合物或其药学上可接受的盐或其形式的步骤 。

    Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
    4.
    发明申请
    Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 审中-公开
    水合晶型的N- [3-氟-4-（氧基）苯基] -N' - （4-氟苯基）环丙烷-1,1-二甲酰胺

    公开(公告)号：US20130143881A1

    公开(公告)日：2013-06-06

    申请号：US13634275

    申请日：2011-03-11

    申请人： Hilary Cannon ,  Feirong Kang ,  Frederick G. Vogt

    发明人： Hilary Cannon ,  Feirong Kang ,  Frederick G. Vogt

    IPC分类号： C07D413/12

    CPC分类号： C07D413/12 ,  C07D215/22

    摘要： This invention relates crystalline hydrates of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Compound (I). The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline hydrate of Compound (I) and a pharmaceutically acceptable excipient.

    摘要翻译： 本发明涉及N- [3-氟-4 - （{6-（甲氧基）-7 - [（3-吗啉-4-基丙基）氧基]喹啉-4-基}氧基）苯基] -N' - （4-氟苯基）环丙烷-1,1-二甲酰胺，化合物（I）。 本发明提供了通过利用蛋白激酶活性的调节来治疗癌症的方法。 本发明还提供含有化合物（I）的结晶水合物和药学上可接受的赋形剂的药物组合物。

    Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
    5.
    发明申请
    Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 有权
    N- [3-氟-4-（氧基）苯基] -N' - （4-氟苯基）环丙烷-1,1-二甲酰胺的结晶形式

    公开(公告)号：US20120270872A1

    公开(公告)日：2012-10-25

    申请号：US13384451

    申请日：2010-07-16

    申请人： Hilary Cannon ,  David Igo ,  Tri Tran

    发明人： Hilary Cannon ,  David Igo ,  Tri Tran

    IPC分类号： C07D413/12 ,  A61P35/00 ,  A61P35/02 ,  A61K31/5377

    CPC分类号： C07D215/20

    摘要： This invention relates to three crystalline forms of N—[3-fluoro-4-((6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl|oxy)phenyl]—N′—(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and a pharmaceutically acceptable excipient.

    摘要翻译： 本发明涉及N- [3-氟-4 - （（6-（甲氧基）-7 - [（3-吗啉-4-基丙基）氧基]喹啉-4-基|氧基）苯基] - N' - （4-氟苯基）环丙烷-1,1-二甲酰胺化合物（I），命名为A型，B型和C型。本发明提供了通过利用蛋白激酶活性的调节来治疗癌症的方法。 本发明还提供含有化合物（I）的结晶形式和药学上可接受的赋形剂的药物组合物。

    Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
    6.
    发明授权
    Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 有权
    N- [3-氟-4 - （{6-（甲氧基）-7 - [（3-吗啉-4-基丙基）氧基] - 喹啉-4-基}氧基）苯基] -N' - （ 4-氟苯基）环丙烷-1,1-二甲酰胺

    公开(公告)号：US08673912B2

    公开(公告)日：2014-03-18

    申请号：US13384451

    申请日：2010-07-16

    申请人： Hilary Cannon ,  David Igo ,  Tri Tran

    发明人： Hilary Cannon ,  David Igo ,  Tri Tran

    IPC分类号： A61K31/535 ,  C07D413/12

    CPC分类号： C07D215/20

    摘要： This invention relates to three crystalline forms of N-[3-fluoro-4-((6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl|oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and a pharmaceutically acceptable excipient.

    摘要翻译： 本发明涉及N- [3-氟-4 - （（6-（甲氧基）-7 - [（3-吗啉-4-基丙基）氧基]喹啉-4-基|氧基）苯基] - N' - （4-氟苯基）环丙烷-1,1-二甲酰胺化合物（I），命名为A型，B型和C型。本发明提供了通过利用蛋白激酶活性的调节来治疗癌症的方法。 本发明还提供含有化合物（I）的结晶形式和药学上可接受的赋形剂的药物组合物。